Prevalence and Molecular Identification of Human Schistosomiasis (NCT07482215) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Prevalence and Molecular Identification of Human Schistosomiasis
359 participantsStarted 2026-05
Plain-language summary
Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period.
* Patients clinically suspected of having schistosomiasis (urinary and/or intestinal) or referred for parasitological examination.
* Individuals (or guardians, in case of minors) who provide written informed consent.
* Patients willing to provide the required biological samples (urine and/or stool).
Exclusion Criteria:
* Patients Received praziquantel within the last 3 months before sample collection
* Patients with incomplete clinical or epidemiological data.
* Patients refusing participation or sample collection.
* Improperly collected, contaminated, or insufficient samples.
* Patients suffering from severe comorbid conditions that may interfere with the interpretation of results (e.g., advanced hepatic or renal failure).
* children with congenital urinary or intestinal anomalies.
What they're measuring
1
prevalence of human schistosomiasis in the study participants